Outrage Over New Cancer Drug Price Pushes Company to Reduce Cost by 50%

Outrage from physicians over the cost of a new cancer drug called Zaltrap has led the drug company to reduce its price by half, according to a New York Times report.

In August, the Food and Drug Administration approved Zaltrap for colorectal cancer treatment. Sanofi, a large French pharmaceutical company, and Regeneron Pharmaceuticals, a small N.Y. biotechnology company, developed the drug, which they initially priced at $11,000 a month — more than double the cost of competing drug Avastin, according to the report.

Physicians from Memorial Sloan-Kettering Cancer Center in New York City spoke out against the exorbitant price of the drug and did not approve the drug for use in the hospital. Three Sloan-Kettering physicians wrote an editorial in The New York Times explaining their decision, noting that the price of drugs and their value often do not correlate.

In response, Sanofi announced it would reduce the price of Zaltrap by half. The official price of Zaltrap will remain the same, but Sanofi will offer 50 percent discounts to physicians and hospitals that purchase the drug and administer it to patients, according to the report.

More Articles on Hospital Oncology:

Charlotte Hungerford Hospital's Cancer Center Would Relocate Under Yale-New Haven Merger
UC San Diego to Close Nevada Cancer Institute After Less Than 1 Year

Covenant HealthCare in Michigan Plans $4M Cancer Center

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars